Last --
Change Today 0.00 / 0.00%
Volume 0.0
MDG On Other Exchanges
Symbol
Exchange
OTC US
Xetra
Xetra
Xetra
All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDG) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGENE AG (MDG)

Related News

No related news articles were found.

medigene ag (MDG) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDG) Details

Medigene AG, a biotechnology company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and breast cancer; and RhuDex, which is in Phase II clinical trial for the oral treatment of autoimmune diseases. It is also developing DC vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment is developing T cell receptor-(TCR) modified T cells, which is in pre-clinical trail for the treatment of advanced cancer; anti-TCR monoclonal antibodies that is in pre-clinical trail to treat T cell-mediated diseases, such as T cell leukaemia or auto-immune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines, which is in pre-clinical trials. It has strategic partnership with Syncore Biotechnologies Ltd. The company was founded in 1994 and is headquartered in Martinsried, Germany.

58 Employees
Last Reported Date: 05/15/14
Founded in 1994

medigene ag (MDG) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €563.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €390.0K
Compensation as of Fiscal Year 2013.

medigene ag (MDG) Key Developments

MediGene AG's Drug Veregen(R) Launches in Canada

MediGene AG announced the launch of its drug Veregen(R) (Sinecatechins Ointment, 10%) for the treatment of genital warts in Canada through the marketing partner Paladin Labs Inc. (who acquired Triton Pharma). Within the scope of the license agreement, Medigene receives sales payments as well as royalties on Veregen(R) sales. Up to now, Veregen(R) is available in the USA, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries. Several marketing partnership agreements have been concluded in Europe, Asia, and America. Veregen(R), a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Sinecatechins 10% & 15% Ointment (Veregen(R)) has been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its current Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes Sinecatechins 15% Ointment (Veregen(R)) as a possible option for treating genital warts.

MediGene AG Scientists Concludes a Project for the Optimized Formulation of a DC Vaccine for the Specific Treatment of Hormone-Refractory Prostate Cancer

Medigene AG scientists has successfully concluded a project for the optimized formulation of a DC vaccine for the specific treatment of hormone-refractory prostate cancer. The project was carried out at the Helmholtz-Zentrum Munchen - German Research Center for Environmental Health, HMGU, and was supported by the Bavarian Ministry of Economic Affairs as part of the m4 Award (funding reference: 1330 683 62/7/12). The optimized vaccine formulation which has been developed will form the basis of discussions that Medigene/Trianta will have with potential partners on the continued clinical development of DC vaccines for prostate cancer. With the m4 Award program, the Bavarian Ministry of Economic Affairs is funding innovations in the field of personalized medicine with high prospects for business success. Over the past two years, the development of an optimized DC vaccine formulation for prostate cancer has received a total of EUR 450,000 through this funding program at the Helmholtz-Zentrum Munchen (HGMU). Medigene acquired the in-licensed technology and the relevant acumen with the acquisition of Trianta Immunotherapies GmbH. Following the positive conclusion of the m4 Award project at the Helmholtz-Zentrum Munchen (HGMU), all members of the DC scientist team are now continuing their development work at Medigene. The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Trianta Immunotherapies GmbH. Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases I/II and II. Medigene/Trianta concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML in 2014.

MediGene AG Reports Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Full Year of 2014

MediGene AG reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company has reported that net loss of EUR 2.04 million, or EUR 0.19 loss per share, compared to a net loss of EUR 3.27 million, or EUR 0.35 loss per share, for the same quarter ended March 31, 2013. Total revenue was EUR 2.43 million, compared to EUR 1.31 million for the same quarter ended March 31, 2013. For the full year of 2014, the company expects revenue to be in the range of EUR 5 million to EUR 6 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDG:GR €0.00 EUR 0.00

MDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $217.69 USD -0.99
Hemispherx Biopharma Inc $0.27 USD +0.0015
Merck & Co Inc $58.08 USD -0.13
View Industry Companies
 

Industry Analysis

MDG

Industry Average

Valuation MDG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit www.medigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.